Morgan Stanley boosted its position in shares of China Biologic Products, Inc. (NASDAQ:CBPO) by 157.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 124,621 shares of the biopharmaceutical company’s stock after buying an additional 76,229 shares during the period. Morgan Stanley owned 0.46% of China Biologic Products worth $12,478,000 as of its most recent SEC filing.
Other hedge funds have also recently made changes to their positions in the company. Eqis Capital Management Inc. raised its stake in shares of China Biologic Products by 51.3% in the first quarter. Eqis Capital Management Inc. now owns 3,220 shares of the biopharmaceutical company’s stock worth $322,000 after buying an additional 1,092 shares during the last quarter. Gateway Advisory LLC purchased a new stake in shares of China Biologic Products during the first quarter worth approximately $480,000. Parametrica Management Ltd purchased a new stake in shares of China Biologic Products during the first quarter worth approximately $598,000. First Trust Advisors LP raised its stake in shares of China Biologic Products by 35.9% in the first quarter. First Trust Advisors LP now owns 11,561 shares of the biopharmaceutical company’s stock worth $1,158,000 after buying an additional 3,053 shares during the last quarter. Finally, Nordea Investment Management AB raised its stake in shares of China Biologic Products by 15.5% in the first quarter. Nordea Investment Management AB now owns 13,200 shares of the biopharmaceutical company’s stock worth $1,322,000 after buying an additional 1,768 shares during the last quarter. 74.09% of the stock is currently owned by hedge funds and other institutional investors.
Shares of China Biologic Products, Inc. (NASDAQ CBPO) opened at 93.21 on Wednesday. China Biologic Products, Inc. has a one year low of $93.08 and a one year high of $133.19. The firm has a 50-day moving average price of $104.90 and a 200-day moving average price of $107.96. The company has a market capitalization of $2.54 billion, a P/E ratio of 24.26 and a beta of 1.70.
China Biologic Products (NASDAQ:CBPO) last released its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 EPS for the quarter, beating analysts’ consensus estimates of $1.30 by $0.05. The business had revenue of $89.28 million during the quarter, compared to analyst estimates of $97.33 million. China Biologic Products had a return on equity of 21.86% and a net margin of 31.55%. China Biologic Products’s quarterly revenue was down 2.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.26 EPS. Equities analysts forecast that China Biologic Products, Inc. will post $4.99 earnings per share for the current year.
A number of analysts have recently commented on the company. Jefferies Group LLC reissued a “buy” rating on shares of China Biologic Products in a research note on Friday, August 4th. Zacks Investment Research downgraded China Biologic Products from a “hold” rating to a “sell” rating in a research report on Monday. BidaskClub downgraded China Biologic Products from a “sell” rating to a “strong sell” rating in a research report on Saturday. Finally, Goldman Sachs Group, Inc. (The) started coverage on China Biologic Products in a research report on Tuesday, May 30th. They set a “neutral” rating for the company. Two research analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company’s stock. China Biologic Products has an average rating of “Hold” and a consensus target price of $132.00.
About China Biologic Products
China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment.
Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
